A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

NCT03740529 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

803

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Mantle Cell Lymphoma
Marginal Zone Lymphoma
B-cell Lymphoma
Small Lymphocytic Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Loxo Oncology, Inc.

Collaborators

[object Object]